JP2019531288A5 - - Google Patents

Download PDF

Info

Publication number
JP2019531288A5
JP2019531288A5 JP2019514710A JP2019514710A JP2019531288A5 JP 2019531288 A5 JP2019531288 A5 JP 2019531288A5 JP 2019514710 A JP2019514710 A JP 2019514710A JP 2019514710 A JP2019514710 A JP 2019514710A JP 2019531288 A5 JP2019531288 A5 JP 2019531288A5
Authority
JP
Japan
Prior art keywords
viral vector
composition
replication
functional group
defective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019514710A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531288A (ja
JP7051132B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/073370 external-priority patent/WO2018050872A1/en
Publication of JP2019531288A publication Critical patent/JP2019531288A/ja
Publication of JP2019531288A5 publication Critical patent/JP2019531288A5/ja
Application granted granted Critical
Publication of JP7051132B2 publication Critical patent/JP7051132B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019514710A 2016-09-16 2017-09-15 ワクチン接種または遺伝子治療のための効率的なウイルスベクターベースの組成物を得るための新規方法 Active JP7051132B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16189276 2016-09-16
EP16189276.5 2016-09-16
PCT/EP2017/073370 WO2018050872A1 (en) 2016-09-16 2017-09-15 A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy

Publications (3)

Publication Number Publication Date
JP2019531288A JP2019531288A (ja) 2019-10-31
JP2019531288A5 true JP2019531288A5 (https=) 2020-07-30
JP7051132B2 JP7051132B2 (ja) 2022-04-11

Family

ID=57083083

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019514710A Active JP7051132B2 (ja) 2016-09-16 2017-09-15 ワクチン接種または遺伝子治療のための効率的なウイルスベクターベースの組成物を得るための新規方法

Country Status (5)

Country Link
US (2) US11166915B2 (https=)
EP (1) EP3512939A1 (https=)
JP (1) JP7051132B2 (https=)
CN (1) CN109952372A (https=)
WO (1) WO2018050872A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11510871B2 (en) 2016-09-16 2022-11-29 Leukocare Ag Method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation
US11166915B2 (en) 2016-09-16 2021-11-09 Leukocare Ag Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
KR102646145B1 (ko) 2018-05-31 2024-03-11 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물
CN112770812A (zh) * 2018-07-24 2021-05-07 沃雅戈治疗公司 产生基因治疗制剂的系统和方法
KR102058961B1 (ko) 2018-07-28 2019-12-24 주식회사 엑소코바이오 엑소좀의 동결건조 방법
KR102163806B1 (ko) * 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
KR102288367B1 (ko) * 2018-11-15 2021-08-11 주식회사 바이오앱 식물체에서 바이러스-유사 입자를 발현하는 재조합 벡터 및 이를 이용한 써코바이러스-유사 입자를 포함하는 백신 조성물의 제조방법
CN112138153B (zh) * 2019-06-28 2022-08-23 怡道生物科技(苏州)有限公司 一种重组带状疱疹疫苗组合物及其用途
WO2021028559A1 (en) 2019-08-14 2021-02-18 Leukocare Ag Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
WO2021243264A2 (en) * 2020-05-28 2021-12-02 Lonza Ltd Formulations for viral vectors
WO2024077052A1 (en) * 2022-10-04 2024-04-11 Emergent Product Development Gaithersburg Inc. Novel vsv virus formulations
CN117065720B (zh) * 2023-07-21 2025-08-22 湖南新九方科技有限公司 一种热解生物炭吸附材料及其制备方法和应用
WO2025125222A1 (en) * 2023-12-11 2025-06-19 Leukocare Ag Compositions comprising viruses, viral vectors or virus-like particles
CN119548638B (zh) * 2025-01-21 2025-10-24 金宇保灵生物药品有限公司 一种活疫苗耐热保护剂及其制备方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3718889A1 (de) 1987-06-05 1988-12-22 Behringwerke Ag Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
DE19508192A1 (de) 1995-03-09 1996-09-12 Behringwerke Ag Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
MXPA05010555A (es) 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
WO2005066333A1 (en) * 2003-12-30 2005-07-21 Aventis Pasteur, Inc. Stabilizing compositions for recombinant viruses
BRPI0511764B8 (pt) 2004-06-01 2021-05-25 Avigen Inc método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav
CA2576519C (en) 2004-08-17 2013-05-21 Regeneron Pharmaceuticals, Inc. Il-1 antagonist formulations
KR101357685B1 (ko) 2005-11-21 2014-02-06 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 재조합 바이러스용 안정화 제형
CA2638811A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
EP1834651A1 (en) * 2006-03-15 2007-09-19 Universiteit Gent Compositions and methods for veterinary vaccination
EP1854478A1 (en) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
GB0715723D0 (en) 2007-08-11 2007-09-19 Ark Therapeutics Ltd Formulation
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
US7998488B2 (en) 2008-11-14 2011-08-16 Baxter International Inc. Vaccine formulations and uses thereof
EP2236520A1 (en) 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
ES2661215T3 (es) * 2009-05-20 2018-03-28 Aeras Composiciones víricas; inmunógenas; secadas por pulverización; estables
US8557253B2 (en) 2009-10-07 2013-10-15 Sanofi Pasteur Sa Stabilizing excipient for inactivated whole virus vaccine
CN102188701A (zh) * 2010-03-12 2011-09-21 上海泽润生物科技有限公司 一种磷酸铝佐剂及其制备方法
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
JP5798356B2 (ja) 2011-04-06 2015-10-21 一般財団法人化学及血清療法研究所 新規インフルエンザワクチン安定化剤
EP2699265B1 (en) 2011-04-20 2019-10-16 Sandoz AG STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc
RU2610174C2 (ru) * 2011-06-24 2017-02-08 Мерк Шарп И Доум Корп. Вакцинные составы против вируса папилломы человека (hpv), содержащие алюминиевый адъювант, и способы их получения
WO2013001034A1 (en) 2011-06-28 2013-01-03 Leukocare Ag Novel stabilisation method for viruses or bacteria
EP2726495B1 (en) 2011-06-28 2019-03-06 Leukocare Ag Method for preventing the unfolding of a (poly)peptide and/or inducing the (re-)folding of a (poly)peptide
RU2654567C2 (ru) 2011-10-11 2018-05-21 Дженентек, Инк. Улучшенная сборка биспецифических антител
CN108771655A (zh) 2011-10-28 2018-11-09 诚信生物公司 含有氨基酸的蛋白质制剂
IN2015MN00038A (https=) 2012-06-25 2015-10-16 Emergent Product Dev Gaithersburg Inc
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
BR112015017307A2 (pt) 2013-03-14 2017-11-21 Abbvie Inc composições de espécies com baixa acidez e métodos para produção e uso das mesmas
KR20160030963A (ko) 2013-07-11 2016-03-21 시노팜 타이완 리미티드 황산화 올리고당을 검출하기 위한 분석 방법
WO2015040234A1 (en) 2013-09-23 2015-03-26 Crucell Holland B.V. Adenovirus formulations
CN105636609A (zh) * 2013-10-25 2016-06-01 白血球保健股份有限公司 一种新颖的生产稳定疫苗的方法
CN105177025B (zh) * 2013-12-03 2022-11-01 北京康乐卫士生物技术股份有限公司 18型重组人乳头瘤病毒病毒样颗粒及其制备方法
WO2015140751A1 (en) 2014-03-21 2015-09-24 Boreal Invest Terminal nanofiltration of solubilized protein compositions for removal of immunogenic aggregates
KR102507483B1 (ko) * 2014-12-01 2023-03-07 트랜스진 안정한 액체 백시니아 바이러스 제제
KR20190053908A (ko) 2016-09-16 2019-05-20 로이코케어 아게 가공 동안 바이오 의약품의 안정화를 위한 신규한 방법
US20190256551A1 (en) 2016-09-16 2019-08-22 Leukocare Ag A novel method of producing a liquid biopharmaceutical drug product
US11510871B2 (en) 2016-09-16 2022-11-29 Leukocare Ag Method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation
US11166915B2 (en) 2016-09-16 2021-11-09 Leukocare Ag Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy

Similar Documents

Publication Publication Date Title
JP2019531288A5 (https=)
JP2018518457A5 (https=)
JP2020508648A5 (https=)
JP2017532966A5 (https=)
JP4902103B2 (ja) 凍結乾燥フォームによる生物活性材料の保存
JP2014516536A5 (https=)
EP4253403A2 (en) Zika virus purification
JP2023513720A5 (https=)
JP2015501840A5 (https=)
JP2016534034A5 (https=)
WO2019060454A3 (en) Adeno-associated virus variant capsids and methods of use thereof
JP2013177473A (ja) 凍結乾燥フォームによる生物活性材料の防腐
JP2018520997A5 (https=)
JP2020528911A5 (https=)
JP2015501656A5 (https=)
JP2014502156A5 (https=)
JP2016506416A5 (https=)
JP2018521028A5 (https=)
JP2019519252A5 (https=)
JP2019526580A5 (https=)
RU2013152648A (ru) Аденовирус обезьян и гибридные аденовирусные векторы
JP2014503206A (ja) アデノウイルス血清型26および血清型35のフィロウイルスワクチン
MX2021015465A (es) Vacuna para fiebre porcina africana.
JP2019531288A (ja) ワクチン接種または遺伝子治療のための効率的なウイルスベクターベースの組成物を得るための新規方法
JP2020533411A5 (https=)